AstraZeneca PLC (ETR:ZEG)

Market Cap	227.45B
Revenue (ttm)	49.54B
Net Income (ttm)	8.01B
Shares Out	n/a
EPS (ttm)	5.13
PE Ratio	28.39
Forward PE	16.93
Dividend	2.91 (1.99%)
Ex-Dividend Date	Aug 7, 2025

Volume	11,767
Average Volume	12,425
Open	145.30
Previous Close	145.80
Day's Range	144.75 - 147.00
52-Week Range	111.00 - 149.50
Beta	0.17
RSI	62.80
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ZEG

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD